A Clinical Study Evaluating the Application of La Roche-Posay's New B5 Multi-Effect Soothing and Repairing Cream on Individuals With Facial Atopic Dermatitis

Inclusion Criteria:

1. Chinese males and females aged 18 to 65 years old (including 18 and 65 yearsold); 2) In good health, without any other chronic diseases or diseases undertreatment; 3) Have received atopic dermatitis drug treatments, including butnot limited to:

1. Topical glucocorticoids (TSC), such as 0.05% fluticasone propionate cream, 0.1%mometasone furoate cream, 0.1% hydrocortisone butyrate cream, 0.1%triamcinolone acetonide cream, 0.25% hydrocortisone cream, 0.05% desonidecream/ointment, etc.;

2. Topical calcineurin inhibitors (TCI), such as 1% pimecrolimus cream, 0.03%/0.1%tacrolimus ointment, etc.;

3. Oral antihistamines, such as cetirizine hydrochloride tablets, loratadinetablets, ebastine tablets, azelastine hydrochloride tablets, etc.;

4. Other topical medications, such as zinc oxide oil (paste), black beandistillate oil ointment, topical phosphodiesterase 4 (PDE-4) inhibitorointment, physiological sodium chloride solution, and other wet dressingmedications, etc.; 4) At the baseline visit (Baseline), as determined by adermatologist:

• Meeting Yao's diagnostic criteria,
• Atopic dermatitis severity is mild (Investigator Global Assessment, IGA ≤ 2 points);
• The condition is in a stable phase and no longer requires topical drugtreatment 5) At the baseline visit (Baseline), trans-epidermal water loss (TEWL) measurement value > 15g/m²/h 6) Voluntarily participate in thetrial, understand and be willing to sign the informed consent form; 7)Willing to follow the study protocol to use the products provided by thestudy throughout the study period, not use other similar products, keepdiaries, and attend regular follow-ups and other trial requirements.

Exclusion Criteria:

1. Study participants who plan to become pregnant, are pregnant, arebreastfeeding, are within 6 months after childbirth, or are unwilling to takenecessary precautions to avoid pregnancy; 2) Study participants with atopicdermatitis in an acute exacerbation phase; 3) Study participants currentlyparticipating in other clinical trials or who have participated in otherclinical trials within the past 3 months; 4) Study participants who usedfunctional moisturizers containing skin microecology-regulating ingredientswithin 1 week before enrollment; 5) Study participants who received physical,chemical, or cosmetic surgical treatments within 3 months before enrollment; 6)Study participants with systemic diseases (severe organ damage), malignanttumors, poorly controlled chronic diseases, acute infectious diseases, majorsurgeries or trauma, psychological or mental disorders, or who require local orsystemic use of drugs/treatments affecting atopic dermatitis due to otherdiseases; 7) Study participants who experience explosive exacerbation of atopicdermatitis lesions after using the treatment regimen; 8) Study participantswith other skin diseases (acne, rosacea, eczema, infections, tumors, etc.) atthe study site or other skin conditions interfering with evaluation (birthmarks, scars, etc.); 9) Study participants with a habit of scratching orsqueezing atopic dermatitis lesions; 10) Study participants with a history ofallergy to the products and related ingredients provided in the study; 11)Study participants with poor compliance, known inability to attend visits ontime, or unwillingness to follow the study protocol during the study period;
2. Other circumstances where the investigator deems it inappropriate for theparticipant to join the study.